Sector News

Pfizer unveils plans for new division post Allergan merger

February 10, 2016
Life sciences

Pfizer has revealed plans for the birth of a new business division, global speciality and consumer brands, after completion of its $160-billion merger with Allergan.

Bill Meury, who currently heads up Allergan’s branded pharmaceuticals segment, is to lead the new unit, which will house Pfizer’s consumer healthcare unit and Allergan’s ophthalmology and aesthetics businesses, including Botox for therapeutic and cosmetic uses.

In other plans, after the transaction closes Pfizer’s Global Innovative Pharma (GIP) business will be combined with the Vaccines, Oncology and Consumer (VOC) division and will operate under the leadership of Albert Bourla, who will become group president, GIP.

Pfizer will continue to manage the combined company’s commercial operations through two distinct businesses: an Innovative Products business and an Established Products business.

The Innovative Products business will be composed of two operating segments: GIP and the Global Specialty and Consumer Brands segment, while the Established Products business will continue to be led by John Young, and consist of the Global Established Pharmaceutical segment, including all legacy Hospira commercial operations.

“We are designing the combined company to preserve and enhance our option to potentially separate the innovative and established businesses into separate companies in the future, and continue to expect to make a decision about any potential separation by no later than the end of 2018,” noted Pfizer’s chief executive Ian Read.

As previously announced, Brent Saunders will take charge as president and chief operating officer of the combined company with responsibility for the oversight of Pfizer and Allergan’s combined commercial businesses, manufacturing and strategy functions.

By Selina McKee

Source: Pharma Times

Related News

May 1, 2021

AbbVie remains one of the best buys in its sector

Life sciences

AbbVie will be among the stocks closing out a busy earnings week. Earnings season tends to draw a lot of interest from investors, but it’s not always the best indicator of a stock’s overall trajectory.

May 1, 2021

Pfizer buys infectious disease biotech Amplyx

Life sciences

Pfizer has bought privately held Amplyx Pharmaceuticals for an undisclosed sum, gaining experimental antifungal and antiviral treatments as the world’s attention turns more toward infectious diseases.

May 1, 2021

Medtronic taps virtual reality ‘flight simulators’ for brain surgery, built from 3D patient scans

Life sciences

Surgical Theater’s technology builds 3D models of an individual patient’s anatomy from CT and MRI scans to offer surgeons an immersive, 360-degree fly-through view.

Send this to a friend